title: A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response.
abstract: OBJECTIVE
  To test the clinical response of systemic lupus erythematosus (SLE) patients to intravenous immunoglobulins (IVIg), and whether the clinical response of IVIg treatment in SLE is accompanied by modification of SLE-associated autoantibodies/antibodies (Abs) and complement levels.
  
  
  METHODS
  Twenty SLE patients were treated with high-dose (2 g/kg) IVIg monthly, in a 5-d schedule. Each patient received between 1-8 treatment courses. They were evaluated for the clinical response, Systemic Lupus Activity Measure (SLAM) score before and after IVIg, levels of antinuclear antibody (ANA), dsDNA (double-stranded DNA), SS-A or SS-B, ENA (extractable nuclear antigens), C3 and C4 levels before and after the treatment, and before and after each treatment course.
  
  
  RESULTS
  A beneficial clinical response following IVIg treatment was noted in 17 out of 20 patients (85%). Few clinical manifestations responded more to treatment: arthritis, fever, thrombocytopenia, and neuropsychiatric lupus. In 9 patients evaluated before and after IVIg, mean SLAM score decreased from 19. 3+/-4.7 to 4+/-2.9 (P<0.0001). There was a tendency towards abnormal levels of complement and Abs before IVIg courses among the treatment responders compared with the non-responders, and similarly the former tended to have normalization of their abnormal levels more than the latter. These differences were found statistically significant only with respect to C4 and SS-A or SS-B levels before IVIg courses.
  
  
  CONCLUSIONS
  IVIg has a high response rate among SLE patients. A combination of clinical manifestations, Abs and complement levels may aid in the future in predicting who among SLE patients will benefit more from IVIg treatment.
authors.affiliation: Department of Medicine 'B' and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Levy
authors.forename: Y
authors.initials: Y
authors.lastname: Sherer
authors.forename: A
authors.initials: A
authors.lastname: Ahmed
authors.forename: P
authors.initials: P
authors.lastname: Langevitz
authors.forename: J
authors.initials: J
authors.lastname: George
authors.forename: F
authors.initials: F
authors.lastname: Fabbrizzi
authors.forename: J
authors.initials: J
authors.lastname: Terryberry
authors.forename: M
authors.initials: M
authors.lastname: Meissner
authors.forename: M
authors.initials: M
authors.lastname: Lorber
authors.forename: J B
authors.initials: JB
authors.lastname: Peter
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000328:Adult; D000918:Antibody Specificity; D001323:Autoantibodies / Q000276:immunology*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous